is a boutique law firm handling complex and class action litigation, including shareholder derivative litigation, securities class actions, data breach and consumer class actions.

Current Securities Class Action Cases

Federman & Sherwood regularly posts press releases about new class action securities cases, which includes the class period and deadlines for appointment of lead plaintiffs.  Please review any of the case listings  below, and if you bought a security during the class period, we invite you to return an investor certification to our office. Our link to an investor certification for any of the cases can be found below each respective press release on that company.  Once completed, please return to our office by email to or fax to (405) 239-2112. 

Current Cases

Keryx Biopharmaceuticals, Inc. [NASDAQ: KERX]

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Keryx Biopharmaceuticals, Inc.

Oklahoma City, OK (August 31, 2016) – On August 26, 2016, a securities class action lawsuit was filed in the United States District Court for the District of Massachusetts against Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is September 2, 2013 through August 1, 2016. More specifically, this litigation was filed because the Company made false and/or misleading statements and/or failed to disclose: (1) that the Company intended to and did contract with only a single contract manufacturer; (2) that the Company lacked adequate inventory controls; (3) that at some point during the Class Period, defendants became aware but did not disclose that its contract manufacturer was experiencing difficulties in production; (4) that these production difficulties would cause the depletion of Keryx's Auryxia inventory, and (5) that, as a result, the Company's financial guidance and statements about Keryx's business, operations, and prospects, were false and misleading.

On August 1, 2016, the Company announced that due to a “production-related issue” with the Company’s only drug manufacturer, patients who use Keryx's kidney drug Auryxia (the Company's only marketed product) will face a supply interruption until at least October. Keryx also withdrew its full-year forecast regarding both sales and financial results. On this news, the Company’s shares fell to close at $4.72 per share.

Plaintiff seeks to recover damages on behalf of all Keryx Biopharmaceuticals, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Tuesday, October 25, 2016 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

To join this class action, click here  to obtain an investor certification. Once complete, please email this form to, fax to us at (405) 239-2112 or send by regular mail to Federman & Sherwood, 10205 North Pennsylvania Avenue, Oklahoma City, OK 73120, ATTN: Robin.

Copyright © 2018 Federman & Sherwood. All Rights Reserved.